LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Elenco Azioni・Roivant Sciences Ltd
Search

Roivant Sciences Ltd

Chiusa

SettoreSettore sanitario

28.4 -2.27

Fortemente da comprare

Aggiornamento del prezzo 10 giu 2026, 19:59 UTC

AcquistaVendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

28.3

Massimo

29.31

Metriche Chiave

By Trading Economics

Entrata

669M

356M

Vendite

521K

2.5M

Margine di Profitto

14,116.825

Dipendenti

721

EBITDA

-65M

-354M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+25.75% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

255M

20B

Apertura precedente

30.67

Chiusura precedente

28.4

Notizie sul Sentiment di mercato

By Acuity

24%

76%

50 / 344 Classifica in Healthcare

Roivant Sciences Ltd Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 giu 2026, 23:36 UTC

Utili

Correction to Oracle Reports Higher 4Q Profit Article

DJ

LeggI

10 giu 2026, 23:19 UTC

Azioni calde

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

DJ

LeggI

10 giu 2026, 23:09 UTC

I principali Market Mover

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

DJ

LeggI

10 giu 2026, 23:04 UTC

Utili

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

DJ

LeggI

10 giu 2026, 20:44 UTC

I principali Market Mover

Caterpillar Raises Quarterly Dividend 8%

DJ

LeggI

10 giu 2026, 23:49 UTC

Acquisizioni, Fusioni, Takeovers

Elliott: Northern Star Should Take No Options Off The Table

DJ

LeggI

10 giu 2026, 23:48 UTC

Acquisizioni, Fusioni, Takeovers

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

DJ

LeggI

10 giu 2026, 23:48 UTC

Acquisizioni, Fusioni, Takeovers

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

DJ

LeggI

10 giu 2026, 23:47 UTC

Discorsi di Mercato

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

DJ

LeggI

10 giu 2026, 23:47 UTC

Acquisizioni, Fusioni, Takeovers

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

DJ

LeggI

10 giu 2026, 23:46 UTC

Acquisizioni, Fusioni, Takeovers

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

DJ

LeggI

10 giu 2026, 23:38 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

DJ

LeggI

10 giu 2026, 23:38 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

DJ

LeggI

10 giu 2026, 23:38 UTC

Discorsi di Mercato

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

DJ

LeggI

10 giu 2026, 23:32 UTC

Discorsi di Mercato

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

DJ

LeggI

10 giu 2026, 23:20 UTC

Discorsi di Mercato

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

DJ

LeggI

10 giu 2026, 22:05 UTC

Discorsi di Mercato

Correction to Bank of Canada Stays on Hold Market Talk

DJ

LeggI

10 giu 2026, 21:57 UTC

Utili

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

LeggI

10 giu 2026, 21:52 UTC

Utili

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

LeggI

10 giu 2026, 21:35 UTC

Utili

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

LeggI

10 giu 2026, 21:22 UTC

Utili

Oracle Stock Slides on Increased Capital Spending -- WSJ

DJ

LeggI

10 giu 2026, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

DJ

LeggI

10 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

DJ

LeggI

10 giu 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

DJ

LeggI

10 giu 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

DJ

LeggI

10 giu 2026, 20:39 UTC

Discorsi di Mercato
Utili

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

DJ

LeggI

10 giu 2026, 20:34 UTC

Utili

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

LeggI

10 giu 2026, 20:33 UTC

Utili

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

DJ

LeggI

10 giu 2026, 20:33 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

DJ

LeggI

10 giu 2026, 20:33 UTC

Discorsi di Mercato
Utili

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

DJ

LeggI

Confronto tra pari

Modifica del prezzo

Roivant Sciences Ltd Previsione

Obiettivo di Prezzo

By TipRanks

25.75% in crescita

Previsioni per 12 mesi

Media 36.53 USD  25.75%

Alto 42 USD

Basso 29.29 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Roivant Sciences Ltd - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

8

Acquista

1

Mantieni

0

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Roivant Sciences Ltd - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

50 / 344 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.

Altri titoli del settore

LLY

Eli Lilly and Co.

1,136.41

↓-0.5%

JNJ

Johnson and Johnson

238.85

↑ +0.91%

ABBV

AbbVie Inc

225.29

↑ +0.05%

UNH

UnitedHealth Group Inc

407.06

↓-1.28%

MRK

Merck & Co Inc.

119

↓-0.38%
help-icon Live chat